Patent · US Active

Predictive marker for EGFR inhibitor treatment

US9121067B2 · kind B2 · utility

0Cited by

7References

1Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Paul Delmar · Basel, CH
Barbara Klughammer · Rheinfelden (Baden), DE
Verena Lutz · Hersbruck, DE
Patricia McLoughlin · Newcastle, GB

Key dates

Filing date	Apr 1, 2013
Grant date	Sep 1, 2015
Priority date	—
Expiry date	Apr 1, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.